Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADIL NASDAQ:HCWB NASDAQ:LIAN NASDAQ:ONCT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADILAdial Pharmaceuticals$0.46+4.4%$0.45$0.22▼$1.30$4.55M14.46 million shs1.95 million shsHCWBHCW Biologics$4.13-2.6%$5.08$3.55▼$100.80$6.10M0.65113,650 shs19,934 shsLIANLianBio$0.05$0.30$0.27▼$4.99$5.87M0.231.04 million shs3 shsONCTOncternal Therapeutics$0.53$0.53$0.53▼$7.17$1.56M1.1899,758 shsN/AThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADILAdial Pharmaceuticals+4.36%-11.46%+37.87%-32.07%-56.24%HCWBHCW Biologics-2.59%-3.05%-0.96%-45.87%-82.90%LIANLianBio0.00%+8.92%-87.26%-73.75%-82.76%ONCTOncternal Therapeutics0.00%0.00%0.00%0.00%-91.90%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADILAdial Pharmaceuticals2.8019 of 5 stars3.85.00.00.00.60.01.3HCWBHCW Biologics2.6849 of 5 stars3.55.00.00.00.03.30.0LIANLianBioN/AN/AN/AN/AN/AN/AN/AN/AONCTOncternal Therapeutics1.5408 of 5 stars3.10.00.00.00.60.81.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADILAdial Pharmaceuticals 3.50Strong Buy$8.001,657.86% UpsideHCWBHCW Biologics 3.00Buy$35.00747.46% UpsideLIANLianBio 0.00N/AN/AN/AONCTOncternal Therapeutics 2.25Hold$10.001,798.97% UpsideCurrent Analyst Ratings BreakdownLatest ONCT, HCWB, LIAN, and ADIL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/29/2025HCWBHCW BiologicsMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$120.00 ➝ $35.00(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADILAdial PharmaceuticalsN/AN/AN/AN/A$0.64 per shareN/AHCWBHCW Biologics$1.45M4.11N/AN/A($6.08) per share-0.68LIANLianBioN/AN/AN/AN/A$2.71 per shareN/AONCTOncternal Therapeutics$790K1.97N/AN/A$10.19 per share0.05Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADILAdial Pharmaceuticals-$13.20M-$1.46N/AN/AN/AN/A-218.88%-177.61%8/12/2025 (Estimated)HCWBHCW Biologics-$30.02M-$23.25N/A∞N/A-1,712.94%N/A-90.09%8/13/2025 (Estimated)LIANLianBio-$110.29M-$0.81N/AN/AN/AN/A-33.17%-30.19%N/AONCTOncternal Therapeutics-$39.48M-$11.69N/AN/AN/A-1,599.95%-177.58%-131.30%N/ALatest ONCT, HCWB, LIAN, and ADIL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025N/AADILAdial Pharmaceuticals-$0.25N/AN/AN/AN/AN/A5/15/2025Q1 2025HCWBHCW BiologicsN/A-$0.05N/A-$0.05N/AN/A5/14/2025Q1 2025ADILAdial Pharmaceuticals-$0.50-$0.34+$0.16-$0.34N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADILAdial PharmaceuticalsN/AN/AN/AN/AN/AHCWBHCW BiologicsN/AN/AN/AN/AN/ALIANLianBioN/AN/AN/AN/AN/AONCTOncternal TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADILAdial PharmaceuticalsN/A1.991.99HCWBHCW BiologicsN/A0.070.07LIANLianBioN/A10.0610.06ONCTOncternal TherapeuticsN/A2.392.39Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADILAdial Pharmaceuticals16.41%HCWBHCW Biologics2.96%LIANLianBio74.85%ONCTOncternal Therapeutics16.05%Insider OwnershipCompanyInsider OwnershipADILAdial Pharmaceuticals4.26%HCWBHCW Biologics42.70%LIANLianBio7.59%ONCTOncternal Therapeutics11.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADILAdial Pharmaceuticals2010.44 million9.99 millionNo DataHCWBHCW Biologics401.44 million825,000Not OptionableLIANLianBio110108.06 million99.86 millionNot OptionableONCTOncternal Therapeutics302.96 million2.63 millionNo DataONCT, HCWB, LIAN, and ADIL HeadlinesRecent News About These CompaniesOncternal sells assets for up to $68m and calls it quitsJuly 1, 2025 | pharmaceutical-technology.comPROR deal: Oncternal sells cancer assets to mystery biotech for $3M, winds down operationsJuly 1, 2025 | fiercebiotech.comFOncternal Therapeutics Announces the Sale of Select Development Programs and the Wind-Down of its OperationsJuly 1, 2025 | globenewswire.comChronic Lymphocytic Leukemia Pipeline Appears Robust With 55+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsightJune 17, 2025 | theglobeandmail.comMarginal Zone Lymphoma Pipeline Appears Robust With 50+ Pharma Companies Actively Working in the Therapeutics Segment | DelveInsightMay 21, 2025 | theglobeandmail.comOncternal Therapeutics Announces Intent to Voluntarily Delist from Nasdaq and Deregister with the SECMarch 7, 2025 | globenewswire.comOncternal Therapeutics (NASDAQ:ONCT) Stock, Short Interest ReportNovember 26, 2024 | benzinga.comOncternal Therapeutics Reports Q3 2024 EarningsNovember 21, 2024 | markets.businessinsider.comOncternal announces workforce reduction, executive changesNovember 17, 2024 | investing.comOncternal announces workforce reduction, executive changesNovember 17, 2024 | investing.comOncternal Therapeutics to Cut Most of Its WorkforceNovember 14, 2024 | marketwatch.comOncternal Therapeutics Faces Workforce Reduction Challenges: Potential Risks and ImplicationsNovember 9, 2024 | markets.businessinsider.comONCT-534 Produces Tolerable Safety Outcomes in Relapsed/Refractory mCRPCOctober 23, 2024 | curetoday.comCWhat’s Causing Oncternal Therapeutics Inc (ONCT) Stock’s -76.41% Drop Over the Last Six Months?October 23, 2024 | bovnews.comBOncternal Therapeutics announces updated data from Phase 1/2 study of ONCT-534October 23, 2024 | markets.businessinsider.comMetastatic Prostate Cancer Pipeline Insights, Treatment Drugs, Clinical Trials, and Companies 2024October 7, 2024 | theglobeandmail.comNorthland Securities Sticks to Its Buy Rating for Heron Therapeutics (HRTX)September 27, 2024 | markets.businessinsider.comEarlier Info on Financial Stress; Obesity and Second Cancers; Carcinogenic Condoms?September 19, 2024 | medpagetoday.comMStockWatch: Moderna’s $1.1B R&D Cut, Profitability Delay Jolt InvestorsSeptember 16, 2024 | genengnews.comGOncternal stops cancer trials and begins search for future business optionsSeptember 14, 2024 | endpts.comENew MarketBeat Followers Over TimeMedia Sentiment Over TimeONCT, HCWB, LIAN, and ADIL Company DescriptionsAdial Pharmaceuticals NASDAQ:ADIL$0.46 +0.02 (+4.36%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$0.38 -0.07 (-16.28%) As of 08/1/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.HCW Biologics NASDAQ:HCWB$4.13 -0.11 (-2.59%) Closing price 08/1/2025 03:59 PM EasternExtended Trading$4.20 +0.08 (+1.82%) As of 08/1/2025 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases. It also develops HCW9201, a cell-based therapy that is in Phase I clinical trials for the treatment of patients with relapsed/refractory acute myelogenous leukemia; and HCW9206, an injectable immunotherapeutic to use as adjuvant for adoptive cell therapy in cancer treatment. HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar, Florida.LianBio NASDAQ:LIAN$0.05 0.00 (0.00%) As of 08/1/2025LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor and NX-13 for ulcerative colitis and Crohn's disease; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus. It has a partnership with Tarsus Pharmaceuticals, Inc. to develop and commercialize TP-03 for the treatment of Demodex blepharitis; and Nanobiotix S.A. to develop and commercialize NBTXR3, a radioenhancer designed to be injected directly into a malignant tumor prior to standard radiotherapy. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.Oncternal Therapeutics NASDAQ:ONCTOncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial. It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T), which is in Phase 1/2 clinical trial for the treatment of hematologic malignancies and solid tumors, as well as targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate in preclinical development for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. The company has license agreements with the Regents of the University of California; Georgetown University; The University of Texas MD Anderson Cancer Center; Shanghai Pharmaceutical (USA) Inc.; and University of Tennessee Research Foundation. Oncternal Therapeutics, Inc. is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/28 - 08/01 Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale Is PG&E an AI Power Play? Why Options Traders Are Betting Big Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
